Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Q4 2025 Earnings Presentation
18 slides from Crinetics Pharmaceuticals's earnings presentation, Feb 26, 2026
Slide 1: Fourth Quarter and Full Year 2025 Financial Results and Business Update
February 26, 2026 Fourth Quarter and Full Year 2025 Financial Results and Business Update
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statement
Slide 3: Introductory Remarks
Introductory Remarks Click icon to add picture Scott Struthers Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 3
Slide 4: 2025: A Breakout Year
2025: A Breakout Year Launched PALSONIFY (paltusotine) Commercial Demonstrated Early Success Towards Market Leadership Built Fully-Integrated Pharmaceutical Company Presented Positive Phase 2 Data on Atumelnant Well-Funded into Showing Potential to 2030 Infrastructure R&D Transform CAH Treatment Ini
Slide 5: PALSONIFY: Strong Commercial Fundamentals Reflect Early Success
PALSONIFY: Strong Commercial Fundamentals Reflect Early Success Patients Providers Payers Activated and Adopting with Recognizing Value Motivated Confidence Proposition >200 >125 ~50% / ~50% Enrollment Forms Unique Palsonify Reimbursed vs. Quickstart Prescribers for Newly Filled Bottles 22/22 Enroll
Slide 6: PALSONIFY: Executing on Our Mission to Become the New Standard of Care in Acromegaly
PALSONIFY: Executing on Our Mission to Become the New Standard of Care in Acromegaly CRINETICS PHARMACEUTICALS | 6
Slide 7: Pipeline Updates
Pipeline Updates Alan Krasner Chief Endocrinologist CRINETICS PHARMACEUTICALS | 7
Slide 8: What's Next: Late-Stage Pipeline of Transformative Assets
What’s Next: Late-Stage Pipeline of Transformative Assets PRODUCT CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATIONAL APPROVED US Patients Acromegaly (US) Paltusotine 36,0001 (Oral SST2 Agonist) Acromegaly (EU) Paltusotine Carcinoid Syndrome 18,000-34,000² (Oral SST2 Agonist) Atu
Slide 9: ADCS: Significant Unmet Need Exists for Patients
ADCS: Significant Unmet Need Exists for Patients Clinical Burden Unmet Need Uncontrolled ADCS Can Have Current Treatments Fall Short of Achieving Debilitating or Fatal Consequences Durable, Well-Tolerated Symptom Control • Estimated 5-year survival rate of 50% if • First-line treatment attempts to s
Slide 10: ACTH Antagonism Targets the Fundamental Driver of ACTH-Dependent Cushing's Syndrome
ACTH Antagonism Targets the Fundamental Driver of ACTH-Dependent Cushing’s Syndrome Disruptions in the HPA Axis Causing ADCS Atumelnant Mechanism of Action in ADCS Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Adrenal (HPA) Axis Cortisol Stress Stress Circadian Clock 2 Higher leve
Slide 11: Atumelnant: Established Proof-of-Concept and Phase 1b/2a Data in ADCS Support Path Forward
Atumelnant: Established Proof-of-Concept and Phase 1b/2a Data in ADCS Support Path Forward Positive Phase 1b/2a Data Upcoming Milestones Phase 1 healthy volunteer data demonstrated Additional data from Phase 1b/2a single-center atumelnant’s ability to reduce and maintain lowered study to be shared a
Slide 12: ADCS: Global Phase 2/3 Operationally Seamless Trial
ADCS: Global Phase 2/3 Operationally Seamless Trial Key Eligibility Criteria: • Male or female ≥16 and <75 years of age • Confirmed ADCS diagnosis • mUFC>1.3x during screening Screening / Phase 21 Phase 32 Open-Label-Extension Washout (12 weeks) (N=Up to 57) (12 weeks) (N=129) (2 years) (3-16 weeks)
Slide 13: Financial Update
Financial Update Click icon to add picture Toby Schilke Chief Financial Officer CRINETICS PHARMACEUTICALS | 13
Slide 14: Financial Results
Financial Results Three Months Ended December 31, Full Year (in millions) 2025 2024 2025 2024 Product Revenue, Net 5.4 0.0 5.4 0.0 Collaboration and 0.7 0.0 2.3 1.0 License Revenue Revenues $ 6.2 $ 0.0 $ 7.7 $ 1.0 Cost of Product Revenue (1.1) 0.0 (1.1) 0.0 R&D Expenses (85.1) (66.6) (332.1) (240.2
Slide 15: $1.4 Billion Cash Balance Funds Current Operating Plan and Strategic Initiatives Into 2030
$1.4 Billion¹ Cash Balance Funds Current Operating Plan and Strategic Initiatives Into 2030 Enables execution on multiple Cash runway based on current operating plan value-creating milestones including: ➢ Commercialization of PALSONIFY $600 Million - $650 Million ➢ Pivotal readouts for ongoing clini
Slide 16: Closing Remarks
Closing Remarks Click icon to add picture Scott Struthers Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 16
Slide 17: Upcoming Milestones
Upcoming Upcoming Milestones Milestones Potential 2026 Milestone Commercial execution of PALSONIFY in the U.S. Paltusotine Advancing paltusotine in other geographies Phase 3 CAREFNDR readout in carcinoid syndrome Phase 2/3 Equilibrium trial initiation in ADCS Additional data from ongoing Phase 1b/2a
Slide 18: Thank You
‘Crinetics Thank You
Crinetics Pharmaceuticals — Q4 2025 Earnings Presentation on 6ix